Novel technologies show promise for future of gene transfer

Several new technologies that could significantly impact the future of gene transfer applications were presented at a conference at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.

  • A team of scientists led by Dr. Luigi Naldini at the San Rafaele Telethon Institute for Gene Therapy (HSR-TIGET) in Milan have developed a new platform for regulating the expression of therapeutic genes, which will have major implications for gene and cell therapy.
  • Dr. Naldini also presented his team's findings on therapeutic use of human stem cells, including potential application to X-linked Severe Combined Immunodeficiency (XSCID or “Bubble-Boy” disease).
  • Dr. Anthony Cheung, from where, presented a safer method to deliver the insulin gene to juvenile diabetes patients using nanoparticles, developed with his colleagues at enGene, Inc., Vancouver.
  • Finally, Dr. Krystof Bankiewicz, University of California-San Francisco, have developed an improved viral vector delivery system that allows real-time, direct MRI monitoring of the distribution of a gene transfer vector within the brain.

The American Society of Gene Therapy is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of gene and related cell and nucleic acid therapies and the promotion of professional and public education in the field. For more information, visit

http://www.asgt.org

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study identifies genes increasing risk of severe COVID-19